US Dollar vs MXN

Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

Regístrate

NRX Nurexone Biologic Inc

0.57

0.00 (0.00%)

27 Sep 2024 - Cerrado

Retrasado por 15 minutos

New Collaboration Could Revolutionize Treatment of Chronic Spinal Cord Injuries

In January 2023,

To read the full story on AllPennyStocks.com, click here.

Nurexone Biologic (TSXV:NRX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024

Haga Click aquí para más Gráficas Nurexone Biologic.

Nurexone Biologic (TSXV:NRX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024

Haga Click aquí para más Gráficas Nurexone Biologic.

Noticias sobre Nurexone Biologic Inc NRX

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
Jueves 26 de Septiembre 2024 (1 día hace) • GlobeNewswire Inc.

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
Jueves 12 de Septiembre 2024 (2 semanas hace) • GlobeNewswire Inc.

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
Viernes 6 de Septiembre 2024 (3 semanas hace) • GlobeNewswire Inc.

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Miércoles 28 de Agosto 2024 (1 mes hace) • GlobeNewswire Inc.

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
Viernes 23 de Agosto 2024 (1 mes hace) • GlobeNewswire Inc.

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
Jueves 15 de Agosto 2024 (1 mes hace) • GlobeNewswire Inc.

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
Viernes 9 de Agosto 2024 (2 meses hace) • GlobeNewswire Inc.

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
Jueves 1 de Agosto 2024 (2 meses hace) • GlobeNewswire Inc.

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
Miércoles 17 de Julio 2024 (2 meses hace) • GlobeNewswire Inc.

Updates from NurExone: Growth Conference Presentation and Website Relaunch
Viernes 5 de Julio 2024 (3 meses hace) • GlobeNewswire Inc.

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
Viernes 28 de Junio 2024 (3 meses hace) • GlobeNewswire Inc.

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
Viernes 21 de Junio 2024 (3 meses hace) • GlobeNewswire Inc.

Más de Nurexone Biologic Inc Artículos de Noticias

SS and C Technologies

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones